Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrimycin for Mycobacterium abscessus pulmonary disease
ChiCTR2100054540Phase 4Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Jan 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of carrimycin in Mycobacterium abscessus lung disease, sponsored by Shanghai Pulmonary Hospital. Primary endpoints: Chest imaging improvement, Early bactericidal activity and 1 more. Started Jan 2022; status: recruiting.
02
Drugs
carrimycin
03
Conditions
Mycobacterium abscessus lung disease
Beyond the preview
Go deeper on ChiCTR2100054540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054540.